Belvedere Trading
VKTX icon

Belvedere Trading’s Viking Therapeutics VKTX Stock Holding History

Belvedere Trading’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,098
Closed -$44.2K – 1011
2024
Q4 		$44.2K Buy
+1,098
New +$62.6K ﹤0.01% 617
2024
Q3 		– Sell
-1,081
Closed -$63.4K – 954
2024
Q2 		$57.3K Sell
1,081
-34,960
-97% -$2.29M ﹤0.01% 497
2024
Q1 		$2.96M Buy
36,041
+19,709
+121% +$877K ﹤0.01% 55
2023
Q4 		$304K Sell
16,332
-4,553
-22% -$59.5K ﹤0.01% 244
2023
Q3 		$231K Sell
20,885
-35,637
-63% -$510K ﹤0.01% 199
2023
Q2 		$916K Buy
56,522
+1,880
+3% +$39.4K ﹤0.01% 83
2023
Q1 		$910K Buy
+54,642
New +$564K ﹤0.01% 80

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Belvedere Trading's VKTX Position: Q1 2025 in Review

Belvedere Trading sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 1,098 shares — an estimated $44.2K sold.

Belvedere Trading first reported a position in VKTX in Q1 2023 and held it in 7 quarters. The position peaked at $2.96M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Belvedere Trading reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Belvedere Trading sold 1,098 Viking Therapeutics shares in Q1 2025, an estimated $44.2K.
  • Belvedere Trading first reported a position in Viking Therapeutics in Q1 2023 and held it in 7 quarters.
  • Belvedere Trading's Viking Therapeutics position peaked at $2.96M in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.